HomeCompareTRPTF vs PFE

TRPTF vs PFE: Dividend Comparison 2026

TRPTF yields 1157.74% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRPTF wins by $68346998.05M in total portfolio value
10 years
TRPTF
TRPTF
● Live price
1157.74%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$68346998.10M
Annual income
$58,420,596,843,186.16
Full TRPTF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — TRPTF vs PFE

📍 TRPTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRPTFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRPTF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRPTF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRPTF
Annual income on $10K today (after 15% tax)
$98,408.10/yr
After 10yr DRIP, annual income (after tax)
$49,657,507,316,708.23/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, TRPTF beats the other by $49,657,507,294,388.33/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRPTF + PFE for your $10,000?

TRPTF: 50%PFE: 50%
100% PFE50/50100% TRPTF
Portfolio after 10yr
$34173499.07M
Annual income
$29,210,298,434,722.44/yr
Blended yield
85.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

TRPTF
No analyst data
Altman Z
-1.6
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRPTF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRPTFPFE
Forward yield1157.74%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$68346998.10M$49.6K
Annual income after 10y$58,420,596,843,186.16$26,258.71
Total dividends collected$67603114.79M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TRPTF vs PFE ($10,000, DRIP)

YearTRPTF PortfolioTRPTF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$126,474$115,774.24$9,153$693.39+$117.3KTRPTF
2$1,503,782$1,368,454.12$8,593$849.25+$1.50MTRPTF
3$16,815,542$15,206,495.51$8,336$1,066.78+$16.81MTRPTF
4$176,910,037$158,917,407.24$8,437$1,384.80+$176.90MTRPTF
5$1,751,827,113$1,562,533,373.62$9,013$1,875.40+$1751.82MTRPTF
6$16,334,987,810$14,460,532,799.09$10,306$2,680.72+$16334.98MTRPTF
7$143,495,132,800$126,016,695,842.98$12,820$4,101.38+$143495.12MTRPTF
8$1,188,116,427,845$1,034,576,635,748.82$17,673$6,826.70+$1188116.41MTRPTF
9$9,277,010,520,357$8,005,725,942,563.04$27,543$12,591.86+$9277010.49MTRPTF
10$68,346,998,099,968$58,420,596,843,186.16$49,560$26,258.71+$68346998.05MTRPTF

TRPTF vs PFE: Complete Analysis 2026

TRPTFStock

Tribe Property Technologies Inc., a property technology company, provides technology-enabled property management services. It operates through Software and Services, and Software Licensing Fees segments. The company engages in the tech-enabled management of condominium and residential communities through its condo-living software platform, and provision of support, community management platform, and related services to real estate developers, condominium and residential communities, and owners and residents through its deficiency management software. It offers its services under the Tribe, Tribe Management, Tribe Property Technologies, Tribe PropTech, Tribe Home, Tribe Rentals, Tribe Home Pro, Home Pro, Gateway, Gateway Property Management, bazinga, bazinga community, bazinga Build, Pendo, and Pendo Rental brand names. The company was formerly known as Cherry Street Capital Inc. and changed its name to Tribe Property Technologies Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Full TRPTF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this TRPTF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRPTF vs SCHDTRPTF vs JEPITRPTF vs OTRPTF vs KOTRPTF vs MAINTRPTF vs JNJTRPTF vs MRKTRPTF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.